How should hair loss that began after starting a GLP‑1 receptor agonist (e.g., semaglutide 0.25 mg weekly) be managed?

Management of GLP-1 Receptor Agonist-Associated Hair Loss

Reassure the patient that this is likely telogen effluvium related to rapid weight loss, which is typically self-limited and reversible, and continue the GLP-1 receptor agonist unless hair loss is severe or causing significant distress.

Understanding the Evidence

The association between GLP-1 receptor agonists and hair loss has emerged primarily from pharmacovigilance data and retrospective cohort studies 1, 2, 3. The strongest evidence links semaglutide and tirzepatide to increased hair loss risk, with pooled odds ratios of 1.40 for any non-scarring alopecia 2. Semaglutide shows a reporting odds ratio of 2.46 and tirzepatide 1.73 in pharmacovigilance databases 2. A target trial emulation study found hazard ratios of 1.37-1.68 for alopecia with GLP-1 receptor agonists compared to SGLT-2 or DPP-4 inhibitors 4.

The hair loss is predominantly telogen effluvium (TE) and androgenetic alopecia (AGA), not alopecia areata 2, 5. The mechanism appears to be rapid weight loss-induced physiologic stress rather than direct drug toxicity 1, 2, 5. Importantly, patients experiencing hair loss had lower follow-up BMI than those without hair loss 5.

Clinical Approach

Initial Assessment

Confirm the diagnosis as telogen effluvium by:

• Timing: Hair loss typically begins 2-4 months after starting therapy or after dose escalation
• Pattern: Diffuse thinning without scarring, positive hair pull test
• Severity: Most cases are mild to moderate; severe cases are more common with Mounjaro (tirzepatide) and Saxenda 6

Evaluate for contributing factors:

• Rate of weight loss (faster loss = higher risk)
• Nutritional deficiencies: ferritin, vitamin D, zinc, B vitamins
• Thyroid function (TSH)
• Baseline protein intake adequacy

Management Algorithm

For mild to moderate hair loss (most cases):

1. Continue the GLP-1 receptor agonist - The metabolic and cardiovascular benefits typically outweigh this self-limited adverse effect 1, 7

2. Optimize nutrition:

   • Ensure adequate protein intake (1.2-1.5 g/kg ideal body weight daily)
   • Supplement identified deficiencies (iron if ferritin <70 ng/mL, vitamin D if <30 ng/mL)
   • Consider multivitamin with biotin, zinc

3. Slow the rate of weight loss if possible:

   • Consider maintaining current dose rather than escalating 3
   • Doses <2 mg weekly semaglutide are rarely implicated 3

4. Reassure and monitor:

   • Explain that telogen effluvium is reversible, typically resolving 3-6 months after the triggering event stabilizes
   • Hair regrowth usually begins even while continuing therapy once weight stabilizes
   • Follow-up in 3 months to assess progression

For severe or distressing hair loss:

1. Consider dose reduction rather than complete discontinuation - some patients respond well to submaximal doses 8

2. If discontinuation is necessary:

   • Switch to a GLP-1 receptor agonist with lower reported risk (liraglutide, dulaglutide, exenatide) 3
   • Consider alternative weight management: SGLT-2 inhibitors, metformin, or topiramate 9

3. Dermatology referral if hair loss persists >6 months after weight stabilization or if scarring alopecia is suspected

Important Caveats

Do not prematurely discontinue effective therapy - the absolute risk of hair loss is low, and discontinuation leads to weight regain and loss of metabolic benefits 9, 2. Weight regain after stopping semaglutide averages 11.6% of lost weight within one year 9.

Female patients are disproportionately affected 3, 6, with males having 64% lower odds of hair loss (adjusted OR 0.36) 6. Married patients showed higher odds (adjusted OR 9.94), possibly reflecting reporting bias 6.

Paradoxically, some cicatricial alopecia may improve - 58% of patients with central centrifugal cicatricial alopecia showed improvement with GLP-1 receptor agonist use 2, suggesting potential anti-inflammatory effects.

The evidence does not support routine discontinuation of GLP-1 receptor agonists for hair loss. The condition is typically self-limited, related to weight loss velocity rather than direct drug toxicity, and resolves with nutritional optimization and weight stabilization while maintaining the substantial metabolic benefits of continued therapy.